Jack is gone but his baggage remains.
No buyout. No offer. No company slashes workforce life this with an offer on the table sorry to say. I wish I was wrong.
Good ol' Jack Thief along with the BoD and Eisai sitting on their hands while the house around them is on fire. No problem milking investors for $100M plus in salaries and benefits. And now after years of talk and hype, Bel-Phen? Nope. Bel-Smoke? Nope. Bel-Met? Nope. Belviq? Nope.
$1B and 10 years invested and here we are barely holding on to $2 per share. Complete and total disaster. I have no faith that Arena even under new leadership is capable of properly bringing ADP-334 and 811 to market. I really don't. Sell while there is still some value left and be done with it.
Just prior to a buyout.
The Jack Lief friends and family charity fund has come to an end. About 18 years too late but better late than never.
A mountain of patents. A molehill of a share price. Patents mean nothing if they are not monetized. Making money is not Arena's specialty.
2 generic combo pills with black box label and no commercials and no print ads beating a novel agent that is safe and effective. A monkey could have done better. Jack is out and eisai needs to go. Get on with the buyout. Arena is toast.
The CFDA granted the company approval to initiate R&D programs on Lorcaserin Hydrochloride tablets and Lorcaserin Hydrochloride API (active pharmaceutical ingredient), the weight-reducing drugs for overweight and obese patients, especially patients who are also suffering with Type 2 diabetes, high blood pressure or high cholesterol.
Jack? Oh wait. Fred? Oh wait.
My issue is that Jack could have let investors know that an informal offer came through and was rejected. Just this little bit of information would have helped to stabilize the stock price at $8 instead of $2. Jack never did anything in his career to help out investors in Arena.
My understanding is that there was a big offer that investors would have loved but was not quite enough for Jack who wanted the moon and the stars combined.
Your theory makes sense especially in regards to the sudden dismissal of Jack, without so much as a warning.
The stock is already down to $2 with downside risk already factored in for at least another year. I don't see it going lower that $1.75, where we were just a few weeks ago.
I'm holding and actually added recently. Jack was the anchor holding back this ship from sailing. I am confident Arena will be better off in the future.
Hopefully Eisai goes the way of Jack. Absolutely tired of their half-hearted efforts over the past 3 years since approval. Truly a sad state of affairs. "Our key areas of commercial focus include oncology and specialty care." Eisai as an oncology pioneer is laughable. Really!
No kidding. They are peddling a failed chemotherapeutic agent as a weight loss drug. What a joke.
ACAD could buy ARNA for a song, consolidate management positions, acquire patents, pipeline, and productive and talented scientists focused on similar techonology. Win win situation.
I am hoping their new ads are modeled after Weight Watchers and Jenny Craig and even Ginko where before and after shots are used. Need a more positive message specifically one that consists of success stories.